Uncategorized

How to Offer Abuse-Deterrent Reformulation Packages Before Drug Patent Loss of Exclusivity — and Win the Contract

The real battleground in pharma isn’t patent expiry—it’s what you do before it.
As soon as a drug’s exclusivity window starts to narrow, the market stops rewarding “good enough” and starts rewarding speed, certainty, and defensibility. That’s why abu…

How to Offer Abuse-Deterrent Reformulation Packages Before Drug Patent Loss of Exclusivity — and Win the Contract Read Post »

Uncategorized

Two Clocks, One Drug: How Patents and FDA Exclusivity Actually Determine When Your Drug Faces Competition

Two clocks. One drug. And a lot of investors betting on the wrong one.
In pharma, timing isn’t just strategy—it’s destiny. Yet too many teams (and too many market narratives) treat “patent expiry” as the finish line. It isn’t.
A recent DrugPatentWatch …

Two Clocks, One Drug: How Patents and FDA Exclusivity Actually Determine When Your Drug Faces Competition Read Post »

Biotechblog
Scroll to Top